Preiss R, Matthias M, Sohr R, Brockmann B, Hüller H
Int J Clin Pharmacol Ther Toxicol. 1985 Apr;23 Suppl 1:S79-88.
After a simultaneous administration of adriamycin and antipyrine to 19 tumor patients, the plasma kinetics of both drugs, the therapeutic effect and the reaction to white blood cells were determined. Antipyrine was given orally at a dose of 875 mg, whereas adriamycin was administered by means of intravenous infusion for 20 min at 60 mg/m2. This application was repeated in eight patients after three weeks. Nine patients had a normal liver function. In ten patients, slight increases were found in individual liver function parameters. All patients were free from metastases of the liver and had bilirubin levels within the normal range. Antipyrine followed an open one-compartment model, whereas adriamycin followed an open two-compartment model. In the mean, t1/2 el and Cl tot of antipyrine were found to be 16.1 h and 32.9 ml/min, t1/2 beta and Cl tot of adriamycin were 23.1 h and 877 ml/min. For antipyrine and adriamycin, these parameters varied interindividually by the factors 2.8 and 3.1, respectively. No correlations were found between the liver function parameters, and the kinetic elimination parameters and the areas under the curves of both drugs. However, significant positive correlations were found to exist between t1/2 el antipyrine and t1/2 beta adriamycin and between the areas under the curves of the two drugs. A relationship between the AUC adriamycinol/AUC adriamycin ratio (which was 0.52 in the mean) and the antipyrine elimination rate did not exist. As compared to 12 persons with no response or progression, the seven patients with partial or complete response had a significantly higher AUC and a significantly lower Cl tot of adriamycin. As compared to the patients with elimination half-life values of less than 20 h, five patients with antipyrine elimination half-life values of more than 20 h had a significantly longer adriamycin elimination beta-phase and a stronger depressive effect on the white blood cells. The results obtained suggest that the antipyrine kinetics in patients with normal or slightly impaired liver function is a useful parameter for an assessment of the depression of white blood cells and the dose adjustment for adriamycin.
对19例肿瘤患者同时给予阿霉素和安替比林后,测定了两种药物的血浆动力学、治疗效果及对白细胞的反应。安替比林口服剂量为875mg,阿霉素以60mg/m²静脉输注20分钟。三周后,8例患者重复此用药方式。9例患者肝功能正常,10例患者个别肝功能参数略有升高。所有患者均无肝转移,胆红素水平在正常范围内。安替比林符合开放一室模型,阿霉素符合开放二室模型。安替比林的平均t1/2el和Cl tot分别为16.1小时和32.9ml/min,阿霉素的t1/2β和Cl tot分别为23.1小时和877ml/min。安替比林和阿霉素的这些参数个体间变化倍数分别为2.8和3.1。未发现肝功能参数与两种药物的动力学消除参数及曲线下面积之间存在相关性。然而,发现安替比林的t1/2el与阿霉素的t1/2β之间以及两种药物的曲线下面积之间存在显著正相关。阿霉素醇/阿霉素的AUC比值(平均为0.52)与安替比林消除率之间不存在关系。与12例无反应或病情进展的患者相比,7例部分或完全缓解的患者阿霉素的AUC显著更高,Cl tot显著更低。与安替比林消除半衰期小于20小时的患者相比,5例安替比林消除半衰期大于20小时的患者阿霉素的消除β相显著更长,对白细胞的抑制作用更强。所得结果表明,肝功能正常或轻度受损患者的安替比林动力学是评估白细胞减少及调整阿霉素剂量的有用参数。